Rigel Pharmaceuticals has signed a licence agreement with Forma Therapeutics for developing, producing and marketing olutasidenib to potentially treat relapsed/refractory acute myeloid leukaemia (R/R AML) and other types of cancer.
Olutasidenib, an investigational agent, is an oral, small molecule inhibitor of mutant isocitrate dehydrogenase 1 (mIDH1) that attaches to and hinders mutated IDH1 enzymes.
Go deeper with GlobalData
According to the latest exclusive, global agreement, Forma is entitled to get $2m in upfront payments.
The company is also eligible for another $17.5m on meeting specific near-term regulatory, approval and initial commercial sale milestones.
Furthermore, on meeting certain development and commercial milestones, Forma will receive payments totalling up to another $215.5m and tiered royalty payments.
See Also:
Rigel will oversee olutasidenib’s potential launch and marketing in the US and plans to enter partnerships to advance its development and commercialisation outside the country.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataA New Drug Application (NDA) for olutasidenib filed by Forma was accepted by the US Food and Drug Administration (FDA), and a regulatory decision is anticipated on 15 February next year.
On obtaining approval, olutasidenib could become the second commercial product of Rigel in haematology-oncology.
In a Phase II registrational study in mIDH1 R/R AML patients, olutasidenib showed a strong duration of response and composite complete remission rate.
Rigel president and CEO Raul Rodriguez said: “Olutasidenib is a potential market-leading treatment that we believe, based on the registrational Phase II data, can improve outcomes in patients with mIDH1+ relapsed or refractory acute myeloid leukaemia, and is a strategic fit for our business.
“This transaction expands our haematology-oncology portfolio and enables us to leverage our strong commercial capabilities to provide a potential new therapy for these patients who remain underserved despite currently available therapies.”
In February last year, Rigel and Eli Lilly and Company signed a global exclusive licence agreement and strategic collaboration for jointly developing and commercialising the former’s R552 for all indications, including autoimmune and inflammatory ailments.
